CD8A and prostate cancer: HLA A2 restricted cytotoxic T-cells (CD8+) that recognize SSX peptides have been isolated from lymph nodes from an SSX2 seropositive melanoma patient [19] and have also been generated for the immunotargeting of prostate cancer cells in vitro[21].